(F) Kaplan–Meier analysis of the DFS in the testing group of luminal breast cancer patients with endocrine therapy after they were stratified into ≥19.5% of CD44-/CD24- (n = 22) vs. <19.5% of CD44-/CD24- tumor cells (n = 19). This evidence concerns the gene CD24 and neoplasm.